Project Grant R01HL174612
- This $153,117 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of the recipient's independent research career as an academic hematopathology physician-scientist. The key objectives are to study hematopoietic stem and progenitor cell (HSPC) crosstalk and transplantation, with the overarching goal of improving HSPC transplantation outcomes. The award period runs from August 1, 2025 to July 31,...
- The federal Project Grant award of $108,512 was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The award will fund research to determine how inflammation is regulated in Runx1-Familial Platelet Disorder (Runx1-FPD), a genetic disorder that increases the risk of hematologic malignancies. The research aims to...
- This $240,552 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a research project titled "Unraveling the Cell Networks in Bone Marrow Through Transcriptomic and Epigenetic Profiling" at the University of Pennsylvania. The project aims to generate a comprehensive single-cell transcriptomic and regulomic map of human bone marrow cells and experimentally establish the mesenchymal cell hierarchy in human bone....
- The federal Project Grant award of $676,748.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research to extend neutrophil survival in neutropenia-related pneumonia. The goal is to explore an alternative strategy for treating and preventing neutropenia-related pneumonia by increasing the lifespan of neutrophils in the lungs of neutropenic patients. Specifically, the research will investigate the role and regulation of gasdermin D...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $536,468 to the University of California, San Diego (UC San Diego) to conduct research on protein aggregation in hematopoietic stem cells (HSCs). The project aims to investigate how HSCs, which regenerate blood and immune cells, preferentially traffic misfolded proteins to aggresomes to maintain fitness and self-renewal, and how this process is impacted by...
- The federal Project Grant award in the amount of $503,870.00 was provided by the National Heart, Lung, and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) to Drexel University. The award is focused on developing a mechanistic understanding of how fetal hemoglobin (HbF) modulates the polymerization of sickle cell hemoglobin (HbS), which is the root cause of sickle cell disease. The research aims to address critical knowledge gaps that limit the rational optimization of...
- This Project Grant award for $445,000.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The funding supports research conducted by The Children's Hospital of Philadelphia (CHOP) to study the role of neutrophil extracellular traps (NETs) in inflammatory and thrombotic diseases. The project aims to characterize the role of NETs in immune homeostasis, determine the mechanisms by which NET stabilization...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $629,498 to The Trustees of the University of Pennsylvania (UEI GM1XX56LEP58) to conduct research aimed at deciphering the molecular mechanisms underlying pediatric interstitial lung disease (CHILD). The key objectives are to: Interrogate the anomalous development of the lung epithelium in CHILD by defining the impact of a specific SFTPC gene mutation on alveolar...
- This $601,169 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to better understand the molecular pathogenesis of myeloproliferative neoplasms (MPNs) and identify new therapeutic targets. Key focus areas include investigating the role of the PTPN1 tumor suppressor gene in MPN progression and the aberrant expression of TIMP-1 in MPN/myelofibrosis. The research is being conducted by the Rector & Visitors...
- This Project Grant award of $125,532.00, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), aims to investigate the disruption of the clonal architecture of human hematopoietic stem cells driven by high-effect somatic and germline genetic variants, and identify the resulting phenotypic changes that lead to impaired stem cell function and increased disease risk with aging. The research will utilize a mitochondrial lineage tracing...
This federal Project Grant award, worth $786,456.00, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of the University of Pennsylvania for the project "IMPACT OF PIGA LOSS ON HEMATOPOIETIC STEM CELL FUNCTION" from August 1, 2025 to May 31, 2030. The goal of this research is to identify the mechanisms underlying the expansion of phosphatidylinositol glycan type A (PIGA) gene-mutated hematopoietic cells in patients with paroxysmal nocturnal hemoglobinuria (PNH) disease. The research aims to determine the effects of PIGA loss on hematopoietic stem and progenitor cell function and identify mechanisms that underlie the clonal expansion of PIGA-deficient cells, with the objective of developing more effective and curative therapies for PNH.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $786.5k | 7/28/25 |